Management guidelines of eosinophilic esophagitis in childhood

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 1, 2014, Pages 107-118

  Papadopoulou, A ^a   Koletzko, S ^b   Heuschkel, R ^c   Dias, J A ^d   Allen, K J ^e   Murch, S H ^f   Chong, S ^g   Gottrand, F ^h   Husby, S ⁱ   Lionetti, P ^j   Mearin, M L ^k   Ruemmele, F M ^l   Schappi M G ^m   Staiano, A ⁿ   Wilschanski, M ^o   Vandenplas, Y ^p  

^a UNIVERSITY OF ATHENS   (Greece)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF WARWICK   (United Kingdom)

^g EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HCA Research   (Denmark)

^j UNIVERSITY OF FLORENCE   (Italy)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^p VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

more..

Author keywords

amino acid based formula; empiric elimination diet; eosinophilic esophagitis; local steroids; systemic steroids; targeted elimination diet

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; INFLIXIMAB; LANSOPRAZOLE; MEPOLIZUMAB; METHYLPREDNISOLONE; MONTELUKAST; OMALIZUMAB; OMEPRAZOLE; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RESLIZUMAB;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILDHOOD; CHRONIC DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIET RESTRICTION; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; EOSINOPHIL; EOSINOPHILIC ESOPHAGITIS; ESOPHAGEAL EOSINOPHILIA; ESOPHAGUS BIOPSY; ESOPHAGUS CANDIDIASIS; ESOPHAGUS DILATATION; ESOPHAGUS STENOSIS; GASTROESOPHAGEAL REFLUX; HUMAN; INFLAMMATORY DISEASE; LOW DRUG DOSE; MAINTENANCE THERAPY; MORBIDITY; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; CHILD; CONSENSUS; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILS; ESOPHAGEAL STENOSIS; ESOPHAGUS; HUMANS; RECURRENCE;

EID: 84893044153     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182a80be1     Document Type: Article

References (100)

1. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133: 1342-63.
2. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3-20.
3. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004;351:940-1.
4. Cherian S, Smith NM, Forbes DA. Rapidly increasing prevalence of eosinophilic oesophagitis in Western Australia. Arch Dis Child 2006;91:1000-4.
5. Dalby K, Nielsen RG, Kruse-Andersen S, et al. Eosinophilic oeso-phagitis in infants and children in the region of southern Denmark: a prospective study of prevalence and clinical presentation. J Pediatr Gastroenterol Nutr 2010;51:280-2.
6. DeBrosse CW, Buckmeier Butz BK, Allen CL, et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia. J Allergy Clin Immunol 2010;126:112-9.
7. van Rhijn BD, VJ, Smout AJ, Bredenoord AJ. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogas-troenterol Motil 2013;25:47-52.
8. Ronkainen J, Talley NJ, Aro P, et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut 2007;56:615-20.
9. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 Years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009;48:30-6.
10. Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 2012;130:461-7.
11. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastro-esophageal reflux disease. Clin Gastroenterol Hepatol 2009;7:1305-13.
12. Sant'Anna AM, Rolland S, Fournet JC, et al. Eosinophilic esophagitis in children: symptoms, histology and pH probe results. J Pediatr Gastroenterol Nutr 2004;39:373-7.
13. Erwin EA, James HR, Gutekunst HM, et al. Serum IgE measurement and detection of food allergy in pediatric patients with eosinophilic esophagitis. Ann Allergy Asthma Immunol 2010;104:496-502.
14. Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009;104:716-21.
15. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313-9.
16. DeBrosse CW, Collins MH, Buckmeier Butz BK, et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia. J Allergy Clin Immunol 2010;126:112-9.
17. Hogan SP, Mishra A, Brandt EB, et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2001;2:353-60.
18. Butt AM, MS, Ng CL, et al. Upregulated eotaxin expression and T cell infiltration in the basal and papillary epithelium in cows' milk associated reflux oesophagitis. Arch Dis Child 2002;87:124-30.
19. Fox VL, Nurko S, Teitelbaum JE, et al. High-resolution EUS in children with eosinophilic "allergic" esophagitis. Gastrointest Endosc 2003;57:30-6.
20. Korsapati H, Babaei A, Bhargava V, et al. Dysfunction of the longitudinal muscles of the oesophagus in eosinophilic oesophagitis. Gut 2009;58:1056-62.
21. Dahms BB. Reflux esophagitis: sequelae and differential diagnosis in infants and children including eosinophilic esophagitis. Pediatr Dev Pathol 2004;7:5-16.
22. Batres LA, Liacouras C, Schnaufer L, et al. Eosinophilic esophagitis associated with anastomotic strictures after esophageal atresia repair. J Pediatr Gastroenterol Nutr 2002;35:224-6.
23. Oliveira C, Zamakhshary M, Marcon P, et al. Eosinophilic esophagitis and intermediate esophagitis after tracheoesophageal fistula repair: a case series. J Pediatr Surg 2008;43:810-4.
24. Gorter RR, Heij HA, van der Voorn JP, et al. Eosinophilic esophagitis after esophageal atresia: is there an association? Case presentation and literature review. J Pediatr Surg 2012;47:e9-13.
25. Mulder DJ, Hurlbut DJ, Noble AJ, et al. Clinical features distinguish eosinophilic and reflux-induced esophagitis: an age-matched, case-controlled study and a novel scoring system. J Pediatr Gastroenterol Nutr 2013;56:263-70.
26. Kirsch R, Bokhary R, Marcon MA, et al. Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;44:20-6.
27. Furuta GT, Kagalwalla AF, Lee JJ, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut 2013;62:1395-405.
28. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant eso-phageal eosinophilia. J Pediatr 2009;154:96-100.
29. Krarup AL, Villadsen GE, Mejlgaard E, et al. Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand J Gastroenterol 2010; 45:273-81.
30. Yoshida N, Uchiyama K, Kuroda M, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol 2004;39:816-22.
31. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14:74-81.
32. Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 2006;55:476-80.
33. Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012;7:e50037.
34. Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from none-osinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;49:393-9.
35. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012;57:1413-9.
36. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011;9:110-7.
37. Dohil R, Newbury RO, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418-29.
38. Untersmayr E, Bakos N, Schöll I, et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J 2005; 19:656-8.
39. Rothenberg ME, Aceves S, Bonis PA, et al. Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis. J Allergy Clin Immunol 2012;130:617-9.
40. Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995;109:1503-12.
41. Spergel JM, Shuker M. Nutritional management of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2008;18:179-94.
42. Spergel JM, Andrews T, Brown-Whitehorn TF, et al. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005;95:336-43.
43. Mosel MA, Schultz LS, Silverman AH, et al. Family psychosocial dysfunction is a prominent feature in eosinophilic esophagitis presenting as pediatric feeding disorder. Gastroenterology 2011; 140:S243-4.
44. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic eso-phagitis. Clin Gastroenterol Hepatol 2006;4:1097-102.
45. Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012;129:1570-8.
46. Markowitz JE, Spergel JM, Ruchelli E, et al. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003;98:777-82.
47. Peterson K, Clayton F, Vinson LA, et al. Utility of an elemental diet in adult eosinophilic esophagitis. Gastroenterology 2011;140:2011;suppl 1:AB180.
48. Lamba R, Feuling MB, Levy MB, et al. Allergy testing in pediatric eosinophilic esophagitis-identification of IgE and delayed hypersen-sitivity food reactions and its impact on management. Gastroenterol-ogy 2011;140:S243.
49. Teitelbaum JE, Fox VL, Twarog FJ, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002;122:1216-25.
50. Spergel JM, Brown-Whitehorn T, Beausoleil JL, et al. Predictive values for skin prick test and atopy patch test for eosinophilic esophagitis. J Allergy Clin Immunol 2007;119:509-11.
51. Mehl A, Niggemann B, Keil T, et al. Skin prick test and specific serum IgE in the diagnostic evaluation of suspected cow's milk and hen's egg allergy in children: does one replace the other? Clin Exp Allergy 2012;42:1266-72.
52. Eggesbo M, Botten G, Halvorsen R, et al. The prevalence of CMA/CMPI in young children: the validity of parentally perceived reactions in a population-based study. Allergy 2001;56:393-402.
53. Klemola T, Vanto T, Juntunen-Backman K, et al. Allergy to soy formula and to extensively hydrolyzed whey formula in infants with cow's milk allergy: a prospective, randomized study with a follow-up to the age of 2 years. J Pediatr 2002;140:219-24.
54. Koletzko S, NB, Arato A, Dias JA, et al. Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroen-terol Nutr 2012;55:221-9.
55. Sicherer S. Epidemiology of food allergy. J Allergy Clin Immunol 2011;127:594-602.
56. Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007;120:638-46.
57. Gonsalves N, Doerfler B, Hirano I. Long term maintenance therapy with dietary restriction in adults with eosinophilic esophagitis. Gas-troenterology 2011;140:S180-1.
58. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis:results of a double-blind, randomised placebo controlled trial. J Allergy Clin Immunol 2012;129:456-63.
59. Rea B, Akhtar N, Jacques K, et al. Epithelial mesenchymal transition induced esophageal remodeling in eosinophilic esophagitis reverses with treatment. Gastroenterology 2011;140:S180.
60. Hackett T. Epithelial-mesenchymal transition in the pathophysiology of airway remodelling in asthma. Curr Opin Allergy Clin Immunol 2012;12:53-9.
61. Gonsalves N, Yang G, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012;42:1451-9.
62. Moawad FJ, Veerappan GR, Lake JM, et al. Correlation between eosinophilic oesophagitis and aeroallergens. Aliment Pharmacol Ther 2010;31:509-15.
63. Scichilone N, Arrigo R, Paternò A, et al. The effect of intranasal corticosteroids on asthma control and quality of life in allergic rhinitis with mild asthma. J Asthma 2011;48:41-7.
64. Elliott EJ, Thomas D, Markowitz JE. Non-surgical interventions for eosinophilic esophagitis. Cochrane Database Syst Rev 2010;3: CD004065.
65. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381-91.
66. Aceves SS, Dohil R, Newbury RO, et al. Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2005;116:705-6.
67. Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:742-9.
68. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165-73.
69. Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 2003;78:830-5.
70. Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006;63: 3-12.
71. Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopatho-logic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2004;2:568-75.
72. Aceves SS, Bastian JF, Newbury RO, et al. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol 2007;102:2271-9.
73. Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-de-pendent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007;19:865-9.
74. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139:1526-37.
75. Gupta SK, Collins MH, Lewis JD, et al. Efficacy and safety of oral budesonide suspension (OBS) in pediatric subjects with eosinophilic esophagitis (EoE): results from the double-blind, placebo-controlled PEER study. Gastroenterology 2011;140:S179.
76. Schroeder SS, Fleischer DM, Masterson JC, et al. Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol 2012;129:1419-21.
77. Dellon ES, Bower JJ, TKeku TO, et al. Markers of tyrosine kinase activity for diagnosis and treatment response in eosinophilic esopha-gitis: a pilot study of pERK 1/2 and pSTAT5. Gastroenterology 2011;140:S187.
78. Helou EF, Simonson J, Arora AS. 3-yr-follow-up of topical corticos-teroid treatment for eosinophilic esophagitis in adults. Am J Gastro-enterol 2008;103:2194-9.
79. Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9:400-9.
80. Liacouras CA, Wenner WJ, Brown K, et al. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998;26:380-5.
81. Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005;3:1198-206.
82. Gupta SK, Peters-Golden M, Fitzgerald JF, et al. Cysteinyl leukotriene levels in esophageal mucosal biopsies of children with eosinophilic inflammation: are they all the same? Am J Gastroenterol 2006;101: 1125-8.
83. Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003;52:181-5.
84. Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011;56:3551-8.
85. Mishra A, Hogan SP, Brandt EB, et al. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 2002;168:2464-9.
86. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010;59:21-30.
87. Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007;120:594-601.
88. Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 2011;170: 1471-4.
89. Fang JC, Hilden K, Gleich GJ, et al. A pilot study of the treatment of eosinophilic esophagitis with omalizumab. Gastroenterology 2011; 140:S235.
90. Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 2001;108:954-61.
91. Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (inflix-imab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008;122:425-7.
92. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacoki-netics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. JAllergy Clin Immunol 2010;125:1237-44.
93. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-31.
94. Schoepfer AM, Gschossmann J, Scheurer U, et al. Esophageal strictures in adult eosinophilic esophagitis: dilation is an effective and safe alternative after failure of topical corticosteroids. Endoscopy 2008; 40:161-4.
95. Pasha SF, Sharma VK, Crowell MD. Current concepts and treatment options in eosinophilic esophagitis. Curr Opin Investig Drugs 2006;7:992-6.
96. Cantu P, Velio P, Prada A, et al. Ringed oesophagus and idiopathic eosinophilic oesophagitis in adults: an association in two cases. Dig Liver Dis 2005;37:129-34.
97. Zimmerman SL, Levine MS, Rubesin SE, et al. Idiopathic eosinophilic esophagitis in adults: the ringed esophagus. Radiology 2005;236:159-65.
98. Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010;105:1062-70.
99. Robles-Medranda C, Villard F, le Gall C, et al. Severe dysphagia in children with eosinophilic esophagitis and esophageal stricture: an indication for balloon dilation? J Pediatr Gastroenterol Nutr 2010;50:516-20.
100. Konikoff MR, Blanchard C, Kirby C, et al. Potential of blood eosi-nophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1328-36.